NASDAQ:CFMSConforMIS Stock Price, Forecast & News

$0.90

+0.00 (+0.12 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.86

Now: $0.90▼

$0.94

50-Day Range

$0.63

MA: $0.85▼

$1.05

52-Week Range

$0.50

Now: $0.90▼

$4.83

Volume721,770 shs

Average Volume609,328 shs

Market Capitalization$64.34 million

P/E RatioN/A

Dividend YieldN/A

Beta2.14

Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
ConforMIS has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $2.50, ConforMIS has a potential upside of 177.2% from its current price of $0.90.
Amount of Analyst Coverage
ConforMIS has only been the subject of 3 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
ConforMIS has received 340 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
ConforMIS has received 282 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
ConforMIS has received 54.66% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote “Outperform” if you believe CFMS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
ConforMIS does not currently pay a dividend.
Dividend Growth
ConforMIS does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, ConforMIS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,807.00 in company stock.
Percentage Held by Insiders
Only 3.19% of the stock of ConforMIS is held by insiders.
Percentage Held by Institutions
35.52% of the stock of ConforMIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for ConforMIS are expected to grow in the coming year, from ($0.53) to ($0.33) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of ConforMIS is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of ConforMIS is -1.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
ConforMIS has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CFMS

Previous Symbol

CUSIPN/A

CIK1305773

Webwww.conformis.com

Phone781-345-9001

Debt

Debt-to-Equity Ratio3.84

Current Ratio2.73

Quick Ratio1.98

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$77.43 million

Price / Sales0.83

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.24 per share

Price / Book3.75

Profitability

EPS (Most Recent Fiscal Year)($0.44)

Net Income$-28,480,000.00

Net Margins-41.29%

Return on Equity-165.61%

Return on Assets-44.12%

Miscellaneous

Employees262

Outstanding Shares71,484,000

Market Cap$64.34 million

Next Earnings Date7/29/2020 (Estimated)

OptionableNot Optionable

Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter.

ConforMIS (NASDAQ:CFMS) Frequently Asked Questions

How has ConforMIS's stock been impacted by COVID-19 (Coronavirus)?

ConforMIS's stock was trading at $0.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CFMS stock has increased by 36.7% and is now trading at $0.9019. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ConforMIS?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ConforMIS.

When is ConforMIS's next earnings date?

ConforMIS is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for ConforMIS.

How were ConforMIS's earnings last quarter?

ConforMIS Inc (NASDAQ:CFMS) issued its quarterly earnings results on Monday, May, 11th. The medical instruments supplier reported ($0.14) EPS for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.04. The medical instruments supplier had revenue of $16.48 million for the quarter, compared to analyst estimates of $18.95 million. ConforMIS had a negative return on equity of 165.61% and a negative net margin of 41.29%. View ConforMIS's earnings history.

What price target have analysts set for CFMS?

3 analysts have issued 12 month target prices for ConforMIS's stock. Their forecasts range from $2.00 to $3.00. On average, they expect ConforMIS's share price to reach $2.50 in the next year. This suggests a possible upside of 177.2% from the stock's current price. View analysts' price targets for ConforMIS.

Has ConforMIS been receiving favorable news coverage?

Headlines about CFMS stock have been trending very negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ConforMIS earned a media sentiment score of -3.7 on InfoTrie's scale. They also assigned news coverage about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutConforMIS.

Are investors shorting ConforMIS?

ConforMIS saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 2,550,000 shares, a decline of 6.9% from the April 30th total of 2,740,000 shares. Based on an average trading volume of 583,700 shares, the short-interest ratio is presently 4.4 days. Approximately 4.0% of the company's stock are sold short. View ConforMIS's Current Options Chain.

Who are some of ConforMIS's key competitors?

Some companies that are related to ConforMIS include Invacare (IVC), RTI Surgical (RTIX), Sientra (SIEN), Lakeland Industries (LAKE), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Histogenics (HSGX), Rewalk Robotics (RWLK), Precision Therapeutics (POAI), Ocugen (OCGN), Bionik Laboratories (BNKL), NanoVibronix (NAOV) and Avitar (AVTI). View all competitors.

What other stocks do shareholders of ConforMIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ConforMIS investors own include Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Cisco Systems (CSCO), AT&T (T), Advanced Micro Devices (AMD), Alibaba Group (BABA), AbbVie (ABBV), Pfizer (PFE) and Starbucks (SBUX).

Who are ConforMIS's key executives?

ConforMIS's management team includes the following people:

Mr. Mark A. Augusti, CEO, Pres & Director (Age 53)
Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 55)
Ms. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 53)
Mr. Ed Kilgallen, VP of Operations
Ms. Lisa M. Donnelly, Sr. VP of Global Marketing

When did ConforMIS IPO?

(CFMS) raised $135 million in an IPO on Wednesday, July 1st 2015. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ConforMIS's stock symbol?

ConforMIS trades on the NASDAQ under the ticker symbol "CFMS."

Who are ConforMIS's major shareholders?

ConforMIS's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.05%), State Street Corp (1.80%), Geode Capital Management LLC (1.64%), AQR Capital Management LLC (0.96%), UBS Group AG (0.95%) and JPMorgan Chase & Co. (0.35%). Company insiders that own ConforMIS stock include Archon Capital Management Llc, Bradley Langdale, Daniel Steines, Erin Henry, Mark A Augusti, Patricia A Davis and Paul S Weiner. View institutional ownership trends for ConforMIS.

Which institutional investors are selling ConforMIS stock?

CFMS stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, JPMorgan Chase & Co., Geode Capital Management LLC, Wells Fargo & Company MN, UBS Group AG, State Street Corp, and BlackRock Inc.. Company insiders that have sold ConforMIS company stock in the last year include Archon Capital Management Llc, Erin Henry, Mark A Augusti, and Paul S Weiner. View insider buying and selling activity for ConforMIS.

Which institutional investors are buying ConforMIS stock?

CFMS stock was acquired by a variety of institutional investors in the last quarter, including Secrest Blakey & Associates LLC, Teton Advisors Inc., Gabelli Funds LLC, Alambic Investment Management L.P., and Two Sigma Advisers LP. View insider buying and selling activity for ConforMIS.

How do I buy shares of ConforMIS?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ConforMIS's stock price today?

One share of CFMS stock can currently be purchased for approximately $0.90.

How big of a company is ConforMIS?

ConforMIS has a market capitalization of $64.47 million and generates $77.43 million in revenue each year. The medical instruments supplier earns $-28,480,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. ConforMIS employs 262 workers across the globe.

What is ConforMIS's official website?

The official website for ConforMIS is www.conformis.com.

How can I contact ConforMIS?

ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff